Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...

Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: a Meta-analysis of Randomized Controlled Trials This study confirms emerging data from a ...

Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

The National Institute for Health and Care Excellence (NICE) is producing guidance on using KRAS mutation testing in the NHS in England. The Diagnostics Advisory Committee has considered the evidence ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Illumina Inc. (NASDAQ:ILMN) ranks among the top NASDAQ stocks with low P/E ratios. On September 23, Illumina Inc. (NASDAQ:ILMN) announced that it would collaborate with several global pharmaceutical ...

Lung cancer is an aggressive type of cancer that begins in the lungs but may spread to other areas of the body. With an estimated 30% 5-year relative survival rate, lung cancer is among the deadliest ...

NICE has been informed of a change to clinical practice in KRAS mutation testing for identifying adults with metastatic colorectal cancer who may benefit from first-line treatment with cetuximab ...